Tandem Diabetes Care, Inc.: depreciation, depletion and amortization
Depreciation, depletion and amortization for Tandem Diabetes Care, Inc. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All Tandem Diabetes Care, Inc. financial histories
What this measure means
Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.
Exact concept: us-gaap:DepreciationDepletionAndAmortization. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2012-01-01 to 2025-12-31. The SEC response was captured on 2026-09-20.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2025-01-01 | 2025-12-31 | 17,666,000 | USD | 2026-02-19 | 10-K · 0001438133-26-000010 |
| 2024-01-01 | 2024-12-31 | 16,607,000 | USD | 2026-02-19 | 10-K · 0001438133-26-000010 |
| 2023-01-01 | 2023-12-31 | 15,715,000 | USD | 2026-02-19 | 10-K · 0001438133-26-000010 |
| 2022-01-01 | 2022-12-31 | 14,330,000 | USD | 2025-02-26 | 10-K · 0001438133-25-000036 |
| 2021-01-01 | 2021-12-31 | 13,845,000 | USD | 2024-02-21 | 10-K · 0001438133-24-000028 |
| 2020-01-01 | 2020-12-31 | 10,451,000 | USD | 2023-02-22 | 10-K · 0001438133-23-000031 |
| 2019-01-01 | 2019-12-31 | 6,072,000 | USD | 2022-02-22 | 10-K · 0001438133-22-000021 |
| 2018-01-01 | 2018-12-31 | 5,821,000 | USD | 2021-02-24 | 10-K · 0001438133-21-000015 |
| 2017-01-01 | 2017-12-31 | 6,866,000 | USD | 2020-02-24 | 10-K · 0001438133-20-000014 |
| 2016-01-01 | 2016-12-31 | 5,489,000 | USD | 2019-02-26 | 10-K · 0001564590-19-004469 |
| 2015-01-01 | 2015-12-31 | 4,829,000 | USD | 2018-03-01 | 10-K · 0001564590-18-004141 |
| 2014-01-01 | 2014-12-31 | 4,389,000 | USD | 2017-03-08 | 10-K · 0001564590-17-003680 |
| 2013-01-01 | 2013-12-31 | 3,167,000 | USD | 2016-02-24 | 10-K · 0001564590-16-013192 |
| 2012-01-01 | 2012-12-31 | 2,032,000 | USD | 2015-02-24 | 10-K · 0001564590-15-000886 |
Related financial histories
- Tandem Diabetes Care, Inc.: total assets
- Tandem Diabetes Care, Inc.: total liabilities
- Tandem Diabetes Care, Inc.: stockholders equity
- Tandem Diabetes Care, Inc.: cash and cash equivalents
- Tandem Diabetes Care, Inc.: net income or loss
- Tandem Diabetes Care, Inc.: operating cash flow
- Tandem Diabetes Care, Inc.: capital expenditure payments
- Tandem Diabetes Care, Inc.: contract revenue excluding tax
- Tandem Diabetes Care, Inc.: financing cash flow
- Tandem Diabetes Care, Inc.: investing cash flow
- Tandem Diabetes Care, Inc.: retained earnings or deficit
- Tandem Diabetes Care, Inc.: basic weighted-average shares
- Tandem Diabetes Care, Inc.: diluted weighted-average shares
- Tandem Diabetes Care, Inc.: basic earnings per share
- Tandem Diabetes Care, Inc.: diluted earnings per share
- Tandem Diabetes Care, Inc.: income tax expense or benefit
- Tandem Diabetes Care, Inc.: net property, plant and equipment
- Tandem Diabetes Care, Inc.: share-based compensation expense
- Tandem Diabetes Care, Inc.: operating income or loss
- Tandem Diabetes Care, Inc.: current assets
- Tandem Diabetes Care, Inc.: current liabilities
- Tandem Diabetes Care, Inc.: current accounts payable
- Tandem Diabetes Care, Inc.: net finite-lived intangible assets
- Tandem Diabetes Care, Inc.: net current accounts receivable
- Tandem Diabetes Care, Inc.: common-stock repurchase payments
- Tandem Diabetes Care, Inc.: operating expenses
- Tandem Diabetes Care, Inc.: net inventory
- Tandem Diabetes Care, Inc.: gross profit
- Tandem Diabetes Care, Inc.: selling, general and administrative expense
- Tandem Diabetes Care, Inc.: research and development expense
- Tandem Diabetes Care, Inc.: common shares outstanding
- Tandem Diabetes Care, Inc.: cash including restricted cash
- Tandem Diabetes Care, Inc.: accumulated other comprehensive income or loss
- Tandem Diabetes Care, Inc.: operating lease right-of-use asset
- Tandem Diabetes Care, Inc.: operating lease liability
- Tandem Diabetes Care, Inc.: long-term debt
- Tandem Diabetes Care, Inc.: gross property, plant and equipment
- Tandem Diabetes Care, Inc.: accumulated depreciation on property, plant and equipment
- Tandem Diabetes Care, Inc.: other noncurrent assets
- Tandem Diabetes Care, Inc.: other noncurrent liabilities
- Tandem Diabetes Care, Inc.: accrued current liabilities
- Tandem Diabetes Care, Inc.: prepaid expenses and other current assets
- Tandem Diabetes Care, Inc.: current contract liabilities
- Tandem Diabetes Care, Inc.: pre-tax income or loss from continuing operations
- Tandem Diabetes Care, Inc.: profit or loss including noncontrolling interests
- Tandem Diabetes Care, Inc.: comprehensive income or loss
- Tandem Diabetes Care, Inc.: net income available to common stockholders
- Tandem Diabetes Care, Inc.: amortization of intangible assets
- Tandem Diabetes Care, Inc.: nonoperating interest expense
- Tandem Diabetes Care, Inc.: other nonoperating income or expense
- Tandem Diabetes Care, Inc.: current income tax expense or benefit
- Tandem Diabetes Care, Inc.: deferred income tax expense or benefit
- Tandem Diabetes Care, Inc.: interest paid, net
- Tandem Diabetes Care, Inc.: proceeds from issuing common stock
- Tandem Diabetes Care, Inc.: operating lease payments
- Tandem Diabetes Care, Inc.: change in accounts receivable
- Tandem Diabetes Care, Inc.: change in inventories
- Tandem Diabetes Care, Inc.: change in accounts payable
Inspect the source
- Entity
- Tandem Diabetes Care, Inc. / CIK 0001438133
- Captured
- 2026-09-20T09:03:40.716Z
- SEC response SHA-256
f2f344ea90e2b976ebe85ea684d39ad4a3fd3d4973cd9d60a12f95dbf6163a69
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001438133.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))